Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers Sells 83,025 Shares

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 83,025 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.30, for a total transaction of $3,511,957.50. Following the completion of the sale, the chief financial officer now owns 231,280 shares of the company’s stock, valued at $9,783,144. This trade represents a 26.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Tempus AI Stock Down 2.4 %

NASDAQ:TEM opened at $41.00 on Friday. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $79.49. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The business’s 50-day simple moving average is $52.64.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. NEA Management Company LLC bought a new stake in shares of Tempus AI in the second quarter valued at approximately $160,048,000. Novo Holdings A S acquired a new position in Tempus AI in the 2nd quarter valued at $142,605,000. Revolution Growth Management Company Inc. bought a new stake in shares of Tempus AI during the 2nd quarter valued at $128,133,000. ARK Investment Management LLC lifted its position in shares of Tempus AI by 355.0% during the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock valued at $134,604,000 after acquiring an additional 1,855,459 shares during the period. Finally, Alphabet Inc. acquired a new stake in shares of Tempus AI during the 2nd quarter worth $54,289,000. 24.22% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on TEM. Guggenheim initiated coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and raised their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th. Bank of America lifted their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday. Wolfe Research initiated coverage on shares of Tempus AI in a research report on Friday. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.